Research programme: SSAO/VAP-1 protein inhibitors - Pharmaxis

Drug Profile

Research programme: SSAO/VAP-1 protein inhibitors - Pharmaxis

Alternative Names: PXS4159; PXS4206

Latest Information Update: 30 May 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmaxis
  • Class Small molecules
  • Mechanism of Action AOC3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 17 May 2015 Boehringer Ingelheim acquires SSAO/VAP-1 protein inhbitors from Pharmaxis
  • 12 Mar 2015 Boehringer Ingelheim enters into an Option and Asset Purchase Agreement with Pharmaxis for SSAO/VAP‐1 inhibitor molecules
  • 22 Jan 2015 Discontinued - Preclinical for Asthma in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top